Equine infectious anemia virus and the ubiquitin-proteasome system

Journal of Virology

Volumn 76, Issue 6, 2002, Pages 3038-3044

  Ott, David E ^a   Coren, Lori V ^a   Sowder II, Raymond C ^a   Adams, Julian ^a   Nagashima, Kunio ^a   Schubert, Ulrich ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; VIRUS PROTEIN;

ARTICLE; DRUG SENSITIVITY; ENZYME INACTIVATION; EQUINE INFECTIOUS ANEMIA VIRUS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RNA VIRUS INFECTION; VIRUS EXPRESSION; VIRUS PARTICLE;

ANIMALS; CELL LINE; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; EQUINE INFECTIOUS ANEMIA; GENE PRODUCTS, GAG; INFECTIOUS ANEMIA VIRUS, EQUINE; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; VIRUS ASSEMBLY;

EID: 0036191078     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.6.3038-3044.2002     Document Type: Article

References (55)

1. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
2. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations
3. The ubiquitin-proteasome proteolytic pathway
4. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation
5. Deubiquitinating enzymes: A new class of biological regulators
6. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
7. Ubiquitination
8. WW domains and retrovirus budding
9. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
10. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations
11. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release
12. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding
13. A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: Implications for viral budding
14. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: Posttranslational modifications, proteolytic processings, and complete amino acid sequences
15. The ubiquitin system
16. Protein regulation by monoubiquitin
17. Ubiquitin-dependent protein degradation
18. Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease
19. Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells
20. Antigen processing by the proteasome
21. Substrate targeting in the ubiquitin system
22. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus
23. Proteasome inhibitors: Valuable new tools for cell biologists
24. Protein measurement with the Folin phenol reagent
25. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
26. Ubiquitination of HIV-1 and MuLV Gag
27. Gag protein of Moloney murine leukemia virus
28. Actin-binding cellular proteins inside human immunodeficiency virus type 1
29. Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain
30. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions
31. Ubiquitin is part of the retrovirus budding machinery
32. Budding of equine infectious anemia virus is insensitive to proteasome inhibitors
33. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
34. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival
35. Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein
36. Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly
37. Ubiquitin in avian leukosis virus particles
38. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway
39. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
40. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2
41. A role for ubiquitin ligase recruitment in retrovirus release
42. Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1
43. Synthesis, assembly, and processing of viral proteins
44. Recognition of the polyubiquitin proteolytic signal
45. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine
46. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag
47. Retroviral virions and genomes
48. Ubiquitin in retrovirus assembly: Actor or bystander?
49. Mass determination of Rous sarcoma virus virions by scanning transmission electron microscopy
50. Themes and variations on ubiquitylation
51. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome
52. An assembly domain of the Rous sarcoma virus Gag protein required late in budding
53. Gag late assembly domain
54. A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release
55. Infectivity of Moloney murine leukemia virus defective in late assembly